

Supplementary Table 3. Overview of the study characteristics and reported prevalence of CAA pathology in patients with AD

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Alakbarzade ²⁶	2021	UK	West	Neuropathologically confirmed AD	Brains for Dementia Research (UK)	15	82.9 (4.8)	53.3	NR	93 (NR/NR/NR/NR)	2.5
Attems ³	2008	Austria	West	Pathologically diagnosed AD (CERAD, Braak, NIA-Reagan)	Three large hospitals in Vienna	760	NR	NR	NR	98 (NR/NR/NR/NR)	1
Bell ⁵⁸	1990	Canada	West	Clinically diagnosed AD, pathologically confirmed	NR	10	79.3 (9)	50.0	NR	60 (NR/NR/NR/NR)	4.5
Bergeron ²⁷	1987	Canada	West	Clinically and pathologically diagnosed AD	Toronto University Hospital	30	73 (8.1)	NR	NR	87 (3/30/53/83)	2
Boon ⁵⁹	2020	The Netherlands	West	Clinically and pathologically diagnosed late onset AD	Netherlands Brain Bank and Normal Aging Brain Collection	21	84.5 (5.9)	57.1	NR	90 (NR/NR/NR/NR)	12
Boyle ⁶⁰	2019	USA	West	Clinical probable AD	ROS & MAP	512	91 (5.9)	71.7	NR	46 (NR/NR/NR/NR)	4
Brayne ²⁹	2009	UK	West	Clinically diagnosed AD (DSM-IV)	CC75C	101	91.2	77.2	NR	60 (34/19/8/27)	3
Chalmers ³⁰	2003	UK	West	Pathologically confirmed AD	SWBB	125	78.6 (8.7)	56.0	NR	95 (63/18/14/32)	3
Chen ⁶¹	2022	USA	West	Autopsy-confirmed AD	NACC	753	82.1 (8.6)	42.9	48.7	0 (NR/NR/NR/46)	8.5
Cruz-Sánchez ³¹	2000	Spain	West	Clinically diagnosed AD (DSM-IV)	NR	28	77 (10)	50.0	NR	61 (NR/NR/NR/NR)	6
Del Ser ⁶²	2005	Canada	West	Clinically diagnosed AD (DSM-III), pathologically confirmed (Braak stage ≥ 4 , CERAD). 22 cases also had IL	Dementia Study Project	57	79.3	66.7	29.8	46 (NR/NR/NR/NR)	1
De Reuck ³⁵	2019	France	West	Demented, pathologically diagnosed AD (Braak V or VI)	Lille University Hospital	92	76	48.9	NR	67 (20/15/33/48)	4.5
Dugger ⁶³	2014	USA	West	Demented, pathologically diagnosed with probable/definite AD (CERAD). Life expectancy <6 months at recruitment	Recruited participants from 22 centers in the USA	38	82 (11.2)	60.5	NR	92 (34/34/24/58)	1
Ellis ⁶⁴	1996	USA	West	Clinically and pathologically (CERAD) diagnosed (possible, probable, or definite) AD	CERAD study	117	76.4	35.9	21.4	83 (57/NR/NR/26)	7
Esiri ³⁸	2015	UK	West	Pathologically diagnosed AD (CERAD)	OPTIMA	154	78.3 (8)	56.5	61.0	94 (NR/NR/9/NR)	4
Esiri ³⁹	1986	UK	West	AD with or without CVD or other CNS disease	Radcliffe Infirmary, Oxford	45	82	66.7	NR	82 (NR/NR/24/NR)	10.5
Fallet-Bianco ⁶⁵	1990	France	West	Clinically demented, microscopically diagnosed AD or mixed dementia (AD and VaD)	Charles Richet Study	42	85.5	NR	NR	74 (NR/NR/NR/NR)	4

Supplementary Table 3. Continued

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Glener ⁶⁶	1981	USA	West	Clinically demented, pathologically diagnosed AD	AFIP	45	68.7	NR	NR	89 (NR/NR/NR/NR)	10
Haglund ⁴¹	2002	Sweden	West	Clinically diagnosed AD, with pathological correlate of varying degrees of AE (15 had AD and VaD)	LLDS	52	78.6 [†]	NR	NR	69 (NR/NR/NR/NR)	4
Hamasaki ⁷	2022	Japan	East Asia	AD according to DSM III-R	Hisayama, Japan	77	89.6 (6.8)	62.3	NR	61 (21/22/18/40)	0
Head ⁴²	2017	USA	West	Pathologically diagnosed AD (Braak stage VI & amyloid plaque stage C, NACC)	UCI ADRC	79	76.1 (12.2)	50.6	NR	72 (41/14/18/32)	7
Helman ⁶⁷	2019	USA	West	Clinically demented, pathologically confirmed AD	NIH NeuroBioBank	12	80.6 (8.2)	33.3	NR	92 (33/8/50/58)	3
Honig ⁴³	2005	USA	West	Clinically demented, pathologically confirmed AD	NACC (1985–2003)	791	78.8 (8.8) [†]	49.6	NR	41 (NR/NR/NR/NR)	7.5
Itoh ⁹	1993	Japan	East Asia	Pathologically diagnosed AD (Khachaturian)	Yokufukai Geriatric Hospital	33	86.5 (7.4)	NR	NR	76 (NR/NR/NR/NR)	3
Jellinger ⁶⁸	1977	Austria	West	Clinically diagnosed probable AD (NINCDS-ADRDA), pathologically confirmed definite AD (CERAD)	3 hospitals in Vienna	92	NR	NR	NR	78 (NR/NR/NR/NR)	12
Jellinger ⁶⁹	2003	Austria	West	Pathologically diagnosed AD	Neurological Institute, Vienna	730	82.4 (4.4)	65.5	NR	98 (NR/NR/NR/24)	1
Jicha ⁷⁰	2006	USA	West	Clinically demented, pathologically diagnosed AD	Mayo Alzheimer Disease Patient Registry	24	89.5	70.8	NR	33 (17/17/0/17)	1
Joachim ⁷¹	1988	USA	West	Clinically and pathologically diagnosed AD	NR	131	77 [†]	NR	NR	100 (NR/NR/NR/ NR)	9.5
Kovacs ¹¹	2013	Austria	West	Clinically diagnosed dementia (14 possible & 8 probable AD)	VITA	22	NR	NR	NR	45 (NR/NR/NR/NR)	4
Kövari ¹²	2013	Switzerland	West	Pathologically diagnosed AD (Braak stage ≥4; 14 pure AD and 11 associated with vascular encephalopathy)	University Hospitals Geneva 2012–2014	10	84.4 (4.1)	50.0	NR	80 (NR/NR/NR/NR)	1
Kövari ¹³	2015	Switzerland	West	Pathologically diagnosed AD (Braak stage ≥4)	University Hospitals Geneva 2007	25	85	NR	NR	68 (NR/NR/NR/NR)	1
Kurucz ⁷²	1981	USA	West	Clinically and pathologically diagnosed AD, infarction present in 11 cases	Warren State Hospital	41	NR	NR	NR	54 (37/NR/17/NR)	3

Supplementary Table 3. Continued

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Leech ⁷³	2001	USA	West	Clinically demented, pathologically confirmed AD (Khachaturian, or NIA-R, or CERAD)	Many hospitals in Oklahoma, Autopsy Assistance Network Oklahoma, Alzheimer's Research Texas Tech University	79	NR	NR	NR	32 (NR/NR/NR/NR)	16.5
Liu ⁷⁴	1999	China	East Asia	Clinically and pathologically diagnosed AD	Beijing Hospital	29	79.9 (7.2)	37.9	NR	86 (NR/NR/NR/NR)	7.5
Lopez ⁷⁵	1991	USA	West	Clinically and pathologically diagnosed AD	PUH & VAMC	40	71.6 (8.1)	47.5	NR	55 (NR/NR/NR/NR)	4
Magaki ⁴⁷	2014	USA	West	Clinically and pathologically diagnosed dementia (AD: 123 pure, AD+LBD, AD+IL: 24 AD+OL)	UCLA ADRC, ECBB	171	NR	NR	NR	73 (19/19/35/54)	7
Mandybur ⁷⁶	1975	UK	West	Clinically and pathologically diagnosed AD	Cincinnati General Hospital	15	69.3 (9.8)	60.0	73.3	87 (27/47/13/60)	7
Mann ⁷⁷	2018	UK	West	Clinically diagnosed late onset AD	MBB	34	80.8 (7.4)	47.1	NR	88 (NR/NR/NR/NR)	3
McAleese ⁴⁹	2019	UK	West	Clinico-pathologically diagnosed AD with >1 deep WML	Institute of Neuroscience, Newcastle	20	83.4 (6.3)	55.0	NR	80 (10/30/40/70)	3.5
McKee ⁵⁰	2006	USA	West	Clinically diagnosed probable AD, CDR 1–3	FHS	13	89 (6)	61.5	NR	100 (NR/NR/NR/ NR)	4
Mountjoy ⁵¹	1982	UK	West	Clinically diagnosed senile dementia of Alzheimer type	Newcastle General Hospital	15	76.2	80.0	NR	60 (NR/NR/NR/NR)	4
Nation ⁷⁸	2012	USA	West	Clinically diagnosed possible (10) or probable (55) AD (NINDS-ARDRA), confirmed by NIA CERAD criteria for probable or definite AD. No VaD or mixed dementia	UCSD-ADRC	65	74.2 (7)	52.3	27.7	80 (NR/NR/NR/NR)	5
Olichney ⁷⁹	2000	USA	West	Clinically and pathologically diagnosed AD (DSM- III, NIH and CERAD)	SD ADRC	306	79.8	47.4	35.9	75 (NR/NR/19/NR)	3
Parker ⁸⁰	1985	USA	West	AD (not further specified)	Tennessee University Hospital	10	77 (70–86)*	40.0	NR	20 (NR/NR/NR/NR)	9
Pirttilä ⁸¹	1996	Finland	West	Clinically diagnosed probable AD (NINCDS-ARDRA), pathologically confirmed definite AD (CERAD)	Kuopo University Hospital	18	84.4 [†]	NR	NR	61 (22/NR/NR/39)	8
Pivtoraiko ⁸²	2021	USA	West	Clinical diagnosis of AD dementia (McKahn)	University of Pittsburgh ADRC	17	84 (10)	17.6	NR	82 (53/18/12/29)	5.5

Supplementary Table 3. Continued

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Premkumar ⁵²	1996	USA	West	Clinically diagnosed probable AD confirmed by pathology (>95% definite AD)	CWRU	190	79	56.8	NR	96 (25/NR/NR/71)	6
Reimand ⁸³	2020	The Netherlands	West	Autopsy-confirmed AD	Amsterdam Dementia Cohort	11	64.3	27.3	NR	100 (NR/NR/NR/ NR)	14
Shim ⁵³	2015	USA	West	Clinically diagnosed AD (criteria comparable to NINCDS-ADRDA)	CCCVD	26	80.7 (9.2)	38.5	23.1	85 (NR/NR/NR/NR)	4
Shinohara ⁸⁴	2016	USA	West	Pathologically diagnosed AD	Mayo Clinic brain bank for neurodegenerative disorders at Jacksonville	428	81*†	57.5	NR	87 (NR/NR/NR/NR)	4
Spina ⁸⁵	2021	USA	West	Pathologically diagnosed AD	Memory and Aging Center, UCSF	48	83 (5.9)	29.2	NR	29 (54/17/8/25)	2
Tomimoto ⁸⁶	1999	Japan	East Asia	Pathologically diagnosed AD (CERAD)	NR	39	79 (9)	NR	NR	97 (15/33/49/82)	8
Vik-Mo ⁸⁷	2019	Norway	West	Clinically diagnosed AD (NINCDS-ADRDA), pathologically confirmed AD	Demvest	31	81.1	67.7	NR	NR (NR/NR/NR/58)	8
Wu ⁵⁵	1992	USA	West	Pathologically diagnosed AD	Albert Einstein College of Medicine, New York	34	80.8 (7.2)	70.6	NR	100 (56/15/29/44)	5
Yamada ⁸⁸	1988	Japan	East Asia	Clinically and pathologically diagnosed AD	Yokufukai Geriatric Hospital	15	83	NR	NR	87 (47/27/13/40)	5
Yamada ⁵⁷	2002	Japan	East Asia	Pathologically diagnosed AD (CERAD)	Kanazawa University Hospital	82	86.1 (7.9)	NR	NR	87 (NR/NR/NR/NR)	2
Yip ⁸⁹	2005	USA	West	Pathologically diagnosed AD (NIA-R criteria for intermediate/high likelihood of AD). 90% Braak stage ≥5	BU ADC Brain Bank	99	75.1 (7)	2.0	NR	91 (NR/NR/NR/NR)	5
Zarow ⁹⁰	1999	USA	West	Clinical-pathologic definite AD (CERAD, Khachaturian) definite AD	Rancho Los Amigos Medical Center	101	77.4 (8.8)	49.5	NR	81 (NR/NR/29/NR)	0

Prevalence of CAA pathology shows the overall prevalence (irrespective of CAA grade), and, if reported, the prevalence of different stages of CAA (mild, moderate, severe, or moderate-to-severe).

AFIP, Armed Forces Institute of Pathology; BU ADC, Boston University AD Center; CC75C, Cambridge City over-75's Cohort; CCCVD, Cognitive Change in Cerebrovascular Disease; CWRU, Case Western Reserve University; Demvest, Dementia study in Western Norway; ECBB, Easton Center Brain Bank; FHS, Framingham Heart Study; LLDS, Lund Longitudinal Dementia Study; MBB, Manchester Brain Bank; NACC, National Alzheimer's Coordinating Center; OPTIMA, Oxford Project to Investigate Memory and Ageing; PUH, Presbyterian University Hospital; ROS, Religious Orders Study; SD ARDC, San Diego Alzheimer's Disease Research Center; SWBB, South Western Brain Bank; UCI ADRC, University of California at Irvine Alzheimer's Disease Research Center; UCLA ADRC, University of California Los Angeles Alzheimer Disease Research Centre; UCSF ADRC, University of California San Diego Alzheimer's Disease research center; UCSF, University of San Francisco; VAMC, Veterans Administration Medical Center; VITA, Vienna Transdanube Aging; AD, Alzheimer disease; AE, Alzheimer's encephalopathy; CAA, cerebral amyloid angiopathy; CDR, clinical dementia rating; CDR-SOB, clinical dementia rating-sum of boxes; CERAD, consortium to establish a registry for Alzheimer's disease; CNS, central nervous system; CVD, cerebrovascular disease; DSM, diagnostic and statistical manual of mental disorders; IL, ischemic lesions; LBD, Lewy body dementia; NIA, national institute on aging; NIA-R, national institute on aging-Reagan; NINCDS-ADRDA, national institute of neurological and communicative disorders and stroke and the Alzheimer's disease and related disorders association; NR, not reported; OL, other lesions; QA, total score of quality assessment; UK, United Kingdom; USA, United States of America; VaD, vascular dementia; WML, white matter lesion.

*Median age and/or age range were reported instead of mean age (SD); †The exact age was not provided, but an estimation could be made based on the available data.